LEXINGTON, Mass., June 17,
2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an
immuno-oncology (I-O) company with
a pipeline of immune checkpoint antibodies,
adoptive cell therapies and cancer
vaccines, announced today that Dr. Jennifer Buell, PhD, President and Chief
Operating Officer of Agenus, will present an update on Agenus'
progress and host one-on-one meetings with investors at the Raymond
James Virtual Human Health Innovation Conference on June 18, 2020.
Date: Thursday, June 18,
2020
Time: 4:20 pm –
4:450 p.m. ET / Virtual Track 1
Webcast: The presentation will be webcast and can be
accessed through the following link:
https://kvgo.com/raymondjames/Agenus-june-2020
About Agenus
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its AgenTus
Therapeutics subsidiary), and proprietary cancer vaccine platforms.
The Company is equipped with a suite of antibody discovery
platforms and a state-of-the-art GMP manufacturing facility with
the capacity to support clinical programs. Agenus is headquartered
in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and twitter.
Contact:
Agenus Inc.
Jennifer
Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-to-present-at-the-raymond-james-virtual-human-health-innovation-conference-301078831.html
SOURCE Agenus Inc.